SCHEMBL7183286

SCHEMBL7183286

COc1cc(OC)c(C(=O)P(=O)(C(=O)c2c(Cl)ccc(Cl)c2OC)c2ccccc2)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
HSD17B10 Q99714 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ABCG2 Q9UNQ0 4/20 0.43
TAS1R3 Q7RTX0 7/20 0.42
TAS1R1 Q7RTX1 7/20 0.42
TAS1R2 Q8TE23 5/20 0.42
KMT2A Q03164 2/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
ATM Q13315 1/20 0.41
TSHR P16473 1/20 0.40
GRM4 Q14833 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
POLB P06746 1/20 0.37
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7186424 0.94 ALDH1A1 (0.43) ALDH1A1HSD17B10KDM4EABCG2TAS1R3
SCHEMBL7174597 0.92 ABCG2 (0.41) ALDH1A1HSD17B10KDM4EABCG2TAS1R3
SCHEMBL7180921 0.89 ABCG2 (0.41) ALDH1A1HSD17B10KDM4EABCG2TAS1R3
SCHEMBL7175458 0.89 ABCG2 (0.46) HSD17B10ABCG2TAS1R3TAS1R1TAS1R2
SCHEMBL7186630 0.89 ALDH1A1 (0.50) ALDH1A1HSD17B10KDM4ETAS1R3TAS1R1
SCHEMBL2768729 0.87 KMT2A (0.47) ALDH1A1HSD17B10KDM4EABCG2KMT2A
SCHEMBL7175981 0.87 ABCG2 (0.44) HSD17B10ABCG2TAS1R3TAS1R1TAS1R2
SCHEMBL7179670 0.86 POLB (0.39) ALDH1A1HSD17B10KDM4EABCG2TAS1R3
SCHEMBL7180872 0.86 ABCG2 (0.39) ALDH1A1HSD17B10ABCG2KMT2ATP53
SCHEMBL7181188 0.85 ALDH1A1 (0.49) ALDH1A1HSD17B10KDM4ETAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ALDH1A1 3416/4885HSD17B10 56/4885KDM4E 3226/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ALDH1A1 3984/4885HSD17B10 42/4885KDM4E 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.